[jondoeuk]

NKX019 update https://www.globenewswire.com/news-release/2022/12/05/2567250/0/en/Nkarta-Announces-Updated-Clinical-Data-on-Anti-CD19-Allogeneic-CAR-NK-Cell-Therapy-NKX019-for-Patients-with-Relapsed-or-Refractory-Non-Hodgkin-Lymphoma.html

Slides https://ir.nkartatx.com/static-files/9cb11d46-a4aa-49a3-baca-dc1a36e5aa60

Webcast https://nkarta-nkx019-clinical-update-conference-call.open-exchange.net/registration

[jondoeuk]

Posters

https://www.nkartatx.com/file.cfm/75/docs/nkarta_sitc_2022_poster_381_nk_cell_expansion.pdf

https://www.nkartatx.com/file.cfm/75/docs/nkarta_sitc_2022_poster_902_nkx019_cd20_mab_combo.pdf

[jondoeuk]

SITC titles

Large-scale expansion and engineering of human NK cells sourced from peripheral blood versus umbilical cord blood

NKX019, an Off-the-Shelf CD19 CAR-NK Cell, mediates improved anti-tumor activity and persistence in combination with CD20-directed therapeutic mAbs

[jondoeuk]

Additional NKX101 and NKX019 clinical data expected by year-end. The data is expected to include safety and activity data for newly enrolled patients at higher dose monotherapy regimen and extended durability follow-up for previously reported patient responses. Also, in June, the company filed a protocol amendment with the FDA for 019 to optimise the trial's design as they prepare for potential dose expansion cohorts. The amended protocol, now in effect, allows for an increased dose of cyclophosphamide with lymphodepletion, in line with 101, and various expansion cohorts evaluating it in combination with rituximab.

[jondoeuk]

Cowen 3rd Annual Oncology Innovation Summit webcast https://wsw.com/webcast/cowen115/nktx/2047935

[crudeoil24]

Time for some momo/fomo to kick in. Let's go NKTX!

[crudeoil24]

Offering is now closed Company raised over $200M within a few sessions. Let's see if tutes accumulate NKTX shares today. Possibly 20.00+ today!

[stock1ace1]

20$

[crudeoil24]

NKTX is a great $$$$$ opportunity.

[crudeoil24]

Not a p&d. Some folks need to learn how to read a corporate balance sheet / and SEC filings.

[crudeoil24]

18.93 > > Looks like NKTX shelf placement is completed. Looks like another $200M in the kitty.

[Saving Grace]

Front Loaded Pump and Dump, They are trying to promote this to death before the Med Beds that cure anything and everything come out.

Japan is already using the Med Beds with indisputable results

Caveat Emptor! with this horseshit scam.

[JamBop]

That would be if the number 15 was the actual value. But why offer an actual value to someone as a valuable transaction?
Makes more sense that 15 is a discount.

[Gator44]

Shouldn't this open at $15 when the market opens for trading ?

[rynlrt]

Price target is 109. Wouldnt consider 18 high

[TheFinalCD]

thats assuming a high price of 18

Message in reply to:
That's only about 10M shares if @ 18.00 price NKTX could absorb that in one session. Could close shelf placement this week + have plenty of cash for their operations & expenses.

[crudeoil24]

That's only about 10M shares if @ 18.00 price NKTX could absorb that in one session. Could close shelf placement this week + have plenty of cash for their operations & expenses.

[crudeoil24]

Turn your monitor upside down! lol

[TheFinalCD]

UP ON OFFERING NEWS

HAVE SEEN IT ALL NOW!!!

[crudeoil24]

I see > NKTX @ 19.84 now. Probably most traders are clueless. Maybe the upcoming big volume days will absorb the $150M shelf placement by April 30.

[TheFinalCD]

$NKTX Nkarta Announces Proposed Public Offering of Common Stock

$150M

[crudeoil24]

Thank you ! I wish Elon Musk buy 50 million shares! lol

NKTX

[TheFinalCD]

18.94 CONGRAT$

[crudeoil24]

PT > 109.00 > Mizuho Maintain Buys On Nkarta, Raises Price Target To $109

[crudeoil24]

NKTX > PHI SLAMMA JAMA!

[crudeoil24]

NKTX > 17.94

[jondoeuk]

Another group plans to test an anti-CD70 CAR-NK (with IL-15) in GBM. Knockout of NR3C1 (steroid receptor pathway) allows for the concurrent use of steroids without negating activity of the therapy

[jondoeuk]

More (preclinical data) from the same group

[jondoeuk]

A PhI is planned

[jondoeuk]

MICA and MICB, as well as ULBP 1-6 expression is tightly restricted in healthy cells, only upregulated during stress and cellular transformation [1], and are recognised by the NKG2D receptor, which activates NK cells [2]. However, looking at just AML, expression can vary [3,4].

So going forward, I hope to see a number of different combinations tested. Bortezomib can increase the cell surface expression of NKG2D ligands, resulting in the increased killing by NK cells [5]. Histone deacetylase inhibitors have also been shown to increase expression of NKG2D ligands [6-8]. Treatment resulted in increased recognition and increased sensitivity to NK cell lysis [9]. In addition, all-trans retinoic acid or valproic acid in patients with AML induced NKG2D ligands on the surface of leukemic cells [10,11].

Finally, the use of a PARP1 inhibitor, could increase AML leukemic stem cell killing [12].

Refs:
1 https://www.annualreviews.org/doi/full/10.1146/annurev-immunol-032712-095951
2 https://www.science.org/doi/10.1126/science.285.5428.727
3 https://www.jimmunol.org/content/189/3/1360.long
4 https://ashpublications.org/blood/article/105/9/3615/21291/Ligands-for-natural-killer-cell-activating
5 https://aacrjournals.org/cancerres/article/68/5/1546/542412/Selective-Induction-of-Expression-of-a-Ligand-for
6 https://aacrjournals.org/cancerres/article/65/23/11136/518911/Cancer-Cells-Become-Susceptible-to-Natural-Killer
7 https://aacrjournals.org/cancerres/article/65/14/6321/518359/Natural-Killer-Cell-Mediated-Lysis-of-Hepatoma
8 https://www.pnas.org/doi/abs/10.1073/pnas.1008522107
9 https://clinicalsarcomaresearch.biomedcentral.com/articles/10.1186/2045-3329-2-8
10 https://www.sciencedirect.com/science/article/pii/S0006497120482278
11 https://www.frontiersin.org/articles/10.3389/fimmu.2020.580328/full
12 https://cancerdiscovery.aacrjournals.org/content/9/9/OF13

[crudeoil24]

Let's go NKTX .....

[jondoeuk]

PR https://www.globenewswire.com/news-release/2022/04/25/2427988/0/en/Nkarta-Announces-Positive-Preliminary-Dose-Finding-Data-for-Two-Lead-Engineered-Natural-Killer-Cell-Programs.html

Slides https://ir.nkartatx.com/static-files/6d097f5f-2f67-4e80-8903-2c96b455b244

[crudeoil24]

PT > 81.00 > Cowen.

[Just-Keep-Trying]

And you too, Sir, did you grab any of this today?????????? Or, are you just talking about it??????

[Just-Keep-Trying]

Did you grab any of this today?????????? Or, are you just talking about it??????

[crudeoil24]

Ongoing shelf placement will drain any gains >

NKTX

[crudeoil24]

Trading float is 19M

NKTX

[crudeoil24]

Shares of Nkarta Inc. (NKTX) skyrocketed 92.8% in very active morning trading, enough to make the stock the biggest gainer and most active listed on major U.S. exchanges, after the biopharmaceutical company announced positive results from a Phase 1 trial of its cancer treatments. The rally comes after the stock closed at a record low of $7.77 on Friday. The company said its NKX101 and NKX019 co-lead candidates showed "striking single-agent activity" in a heavily pretreated patient populations, with an "exceptional safety provide" without side effects associated with CAR T cell therapies. Cowen analyst Salim Syed reiterated his buy rating and $81 stock price target, which implies TK% upside from current levels. "Investor sentiment was pretty low going into this readout," Syed wrote in a note to clients. "And of course, we still need durability data and more n, but showing these responses today, is a major plus, and street trading valuations should now move substantially higher for both programs." The stock has now lost 2.4% year to date, while the iShares Biotechnology ETF (IBB) has dropped 19.7% and the S&P 500 has declined 11.1%.

-Tomi Kilgore


(END) Dow Jones Newswires

[crudeoil24]

NKTX @ 15.15 up 96 % after positive CC.

[TheFinalCD]

previous close 7.77 almost +$10 WOW

[crudeoil24]

Data @ CC > 8:00AM EST

NKX101 – 3 of 5 patients with relapsed / refractory AML treated with a three-dose regimen consisting of 1B or 1.5B CAR NK cells per dose achieved complete response with full hematologic recovery (60% CR rate); 2 of 3 CRs are MRD negative

NKX019 – 5 of 6 patients with relapsed / refractory NHL treated with a three-dose regimen consisting of 1B CAR NK cells per dose achieved response (83% ORR) and 3 of 6 achieved complete response (50% CR rate); responses included DLBCL

No cytokine release syndrome (CRS), neurotoxicity or graft versus host disease (GvHD) reported for either program

Higher dose regimen of 1.5 billion x 3 doses of CAR NK cells is being evaluated in both programs

Updated data will be submitted for presentation at a future medical meeting

Conference call scheduled for today, April 25 at 8:00 am ET

[jondoeuk]

Link to webcast https://www.veracast.com/webcasts/clients/webcasts/KdH3SE.cfm

[jondoeuk]

The company will host a conference call on Mon, April 25, at 8:00 am ET to review clinical data from its ongoing PhI clinical trials assessing two lead clinical programs, NKX101 and NKX019. Leading investigators from the two clinical trials will join management in the discussion.